26,766 RSUs reported by Legend Biotech (LEGN) director Peter Salovey

Rhea-AI Filing Summary

Legend Biotech Corp director Peter Salovey filed an initial ownership report showing 26,766 restricted share units (RSUs) tied to the company’s ordinary shares. Each RSU represents a right to receive one ordinary share upon settlement, and the shares may also be represented by ADSs, with each ADS equal to two ordinary shares.

The filing notes that 5,216 RSUs have already settled. Of the remaining awards, 7,306 RSUs are scheduled to vest in six equal quarterly installments beginning on March 20, 2026. Another 14,244 RSUs are scheduled to vest with 25% on June 20, 2026 and the balance in eight equal quarterly installments, subject to Salovey’s continued service to the company.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Salovey Peter

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	26,766(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Represents 26,766 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 5,216 RSUs have settled, with the remainder vesting (i) as to 7,306 RSUs, in 6 equal quarterly installments beginning on March 20, 2026, and (ii) as to 14,244 RSUs, with 25% of the shares vesting on June 20, 2026 with the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Pepin, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did Peter Salovey report in his Form 3 for Legend Biotech (LEGN)?

Peter Salovey reported 26,766 restricted share units (RSUs) tied to Legend Biotech’s ordinary shares. These RSUs represent a contingent right to receive one ordinary share each upon settlement, reflecting his initial beneficial ownership as a director.

How many Legend Biotech RSUs held by Peter Salovey have already settled?

The filing states that 5,216 RSUs have settled for Peter Salovey. The remaining units are unvested and will vest over time according to specified quarterly schedules, contingent on his continued service to Legend Biotech on each vesting date.

What is the vesting schedule for Peter Salovey’s remaining 7,306 Legend Biotech RSUs?

The filing shows that 7,306 RSUs will vest in six equal quarterly installments. Vesting begins on March 20, 2026, with additional installments on subsequent quarterly dates, assuming Salovey continues serving the company on each vesting date.

How will the 14,244 RSUs reported by Peter Salovey vest at Legend Biotech?

For the 14,244 RSUs, 25% will vest on June 20, 2026, and the remainder will vest in eight equal quarterly installments thereafter. Each installment is contingent on Peter Salovey’s continued service to Legend Biotech through the applicable vesting date.

How are Legend Biotech ordinary shares and ADSs related in Peter Salovey’s Form 3?

The filing explains that Legend Biotech’s ordinary shares may be represented by American Depositary Shares (ADSs). Each ADS represents two ordinary shares, providing investors with an equivalent interest in the underlying ordinary shares reported through the RSUs.

What does each Legend Biotech RSU reported by Peter Salovey represent?

Each RSU reported by Peter Salovey represents a contingent right to receive one ordinary share of Legend Biotech upon settlement. Settlement and vesting depend on the defined schedule and his continued service to the company on the relevant vesting dates.